Everyone Wants a Piece of this Scottish Biotech’s AI

Evotec has doubled down on its investment in Exscientia: the German outfit just announced it has invested €15M to take a minority stake.

Sanofi, GSK and Evotec have all jumped at the opportunity to work with Exscientia, a Scottish startup founded in 2012 and incubating in Dundee. Now, Evotec has gone beyond the initial immuno-oncology deal and invested €15M in Exscientia to accelerate its growth in exchange for a minority stake, making Evotec the first strategic shareholder in the Scotland-based company.  This follows partnerships between Exscientia and two big pharma, Sanofi and most recently GSK that could be worth nearly €300M combined.

AI in biotech has really taken off, particularly for Alzheimer’s research. The biggest name in the European arena is BenevolentAI, whose CEO, Jackie Hunter, I recently interviewed about the company’s strategy. Despite its establishment as a leader with its recent purchase of a NVIDIA supercomputer, BenevolentAI seems to have found a competitor in this Scottish biotech, evidenced by pharma’s interest in the startup.

Image via strelka / shutterstock.com

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.